STOCK TITAN

Legend Biotech Corporation - LEGN STOCK NEWS

Welcome to our dedicated page for Legend Biotech Corporation news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech Corporation stock.

Legend Biotech Corporation (Symbol: LEGN) is an emerging clinical-stage biopharmaceutical company dedicated to the development and commercialization of cutting-edge immunotherapy technology aimed at curing cancer. The company leverages its expertise in immunology and molecular biology to advance a robust pipeline of chimeric antigen receptor (CAR) product candidates designed to address a variety of liquid and solid tumors.

Legend Biotech's primary focus is on developing CAR-T cell therapies, which have shown great promise in clinical trials. One of their flagship products, LCAR-B38M/JNJ-4528, targets multiple myeloma, a previously incurable blood cancer. Recent clinical trial results have demonstrated significant success in treating patients with refractory and relapsed multiple myeloma, showcasing the potential of their proprietary CAR-T technology.

Founded with a vision to revolutionize cancer treatment, Legend Biotech aims to safely and effectively treat previously untreatable cancers with finely-tuned CAR-T products developed through their innovative technology platform. The company's ambition has been notably fulfilled by their advances in the CARs field, as evidenced by their promising clinical outcomes.

Legend Biotech collaborates extensively with leading immunologists and molecular biologists to enhance their research and development efforts. They generate significant revenue from license and collaboration agreements, primarily from the United States.

Stay updated with the latest news and developments regarding Legend Biotech Corporation on this dedicated page.

Rhea-AI Summary

Legend Biotech (NASDAQ: LEGN) will host an investor conference call on August 9, 2024, at 8:00 am ET to discuss its Q2 2024 results. The company's senior leaders will review the quarterly performance during the webcast. Investors can join the live audio webcast via a provided weblink, and a replay will be accessible in the Investor Relations section of Legend Biotech's website approximately two hours after the call concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
conferences earnings
-
Rhea-AI Summary

Legend Biotech (NASDAQ: LEGN) announced positive overall survival results from the Phase 3 CARTITUDE-4 trial, evaluating CARVYKTI® in relapsed and lenalidomide-refractory multiple myeloma. The trial showed statistically significant and clinically meaningful improvement in overall survival compared to PVd and DPd regimens.

The safety profile was consistent with previous data, and no new safety signals were identified. The results will be shared with regulatory agencies for potential updates. CARVYKTI® had already gained FDA approval on April 5, 2024.

However, the study reported a higher percentage of early deaths in the CARVYKTI® arm, primarily due to adverse events and infections. Other risks include cytokine release syndrome, neurologic toxicities, and secondary malignancies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
-
Rhea-AI Summary

Legend Biotech shared promising data on CARVYKTI® (ciltacabtagene autoleucel) for treating multiple myeloma at ASCO and EHA 2024. The CARTITUDE-2 Cohort D study showed a 94% overall response rate and 80% MRD negativity with one-time CARVYKTI® infusion. CARTITUDE-4 analysis revealed CARVYKTI® improved progression-free survival (PFS) vs standard therapy in high-risk patients. The efficacy of CARVYKTI® was consistent across different cytogenetic abnormalities. However, safety concerns including CRS, ICANS, and infections were noted.

These findings support CARVYKTI®'s potential as a new standard of care for high-risk multiple myeloma patients refractory to lenalidomide. Further Phase 3 studies are underway to evaluate CARVYKTI® in earlier treatment settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
none
Rhea-AI Summary

Legend Biotech (NASDAQ: LEGN), a global leader in cell therapy, announced that CEO Ying Huang, Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference. This event will take place in New York, NY, on June 6, 2024, at 10:30 a.m. ET. Investors and other interested parties can view the live webcast through the Investor Relations section of Legend's website. A replay will be available approximately 48 hours after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
conferences
-
Rhea-AI Summary

Legend Biotech (NASDAQ: LEGN) will present new data on its CAR-T cell therapy, CARVYKTI®, for multiple myeloma at the 2024 ASCO and EHA events.

Significant upcoming presentations include:

  • Phase 2 CARTITUDE-2 study data will be presented at ASCO and EHA.
  • Phase 3 CARTITUDE-4 study data regarding high-risk multiple myeloma will also be showcased.

Key studies analyze CARVYKTI®'s effectiveness in patients with different risk profiles and those who had suboptimal responses to previous treatments.

Despite positive advancements, warnings about severe side effects such as cytokine release syndrome, neurologic toxicities, and other serious adverse events were noted.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.84%
Tags
none
-
Rhea-AI Summary

Legend Biotech (NASDAQ: LEGN) reported first quarter 2024 financial results with CARVYKTI® net trade sales of $157 million, FDA label expansion, and a milestone payment of $45 million. The company's cash position stands at $1.3 billion, ensuring financial stability until 2026. Legend Biotech's recent developments include increased manufacturing capacity, regulatory approvals in the U.S., Europe, and Brazil, and a Master Manufacturing and Supply Services Agreement with Novartis. The company's ESG report aligns with SASB standards, and the collaboration revenue has shown significant growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
Rhea-AI Summary
Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) has been approved by the European Commission for the treatment of relapsed and refractory multiple myeloma. This approval was granted based on positive results from the CARTITUDE-4 study, showing significant improvement in progression-free survival compared to standard treatments. The approval may revolutionize the treatment landscape for multiple myeloma patients, offering new hope and options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
-
Rhea-AI Summary
Legend Biotech (LEGN) will host a conference call to review first-quarter 2024 results. Senior leaders will provide an overview of the company's performance. Investors can join the live webcast and access a replay version later.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences earnings
-
Rhea-AI Summary
Legend Biotech's CARVYKTI® receives FDA approval for treating relapsed or refractory multiple myeloma, offering a new treatment option with improved progression-free survival. The therapy targets B-cell Maturation Antigen, providing hope for patients and physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN) releases its inaugural Environmental, Social & Governance (ESG) report, showcasing commitment to patients, employees, and communities. Key pillars include patient care, innovation, employee engagement, community involvement, operational efficiency, and integrity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
none

FAQ

What is Legend Biotech Corporation's main focus?

Legend Biotech focuses on developing and commercializing immunotherapy technology to treat various types of cancer.

What is CAR-T therapy?

CAR-T therapy involves modifying T cells to express chimeric antigen receptors that can target and destroy cancer cells.

What is Legend Biotech's lead product candidate?

Their lead product candidate is LCAR-B38M/JNJ-4528, a CAR-T cell therapy for treating multiple myeloma.

What types of cancer does Legend Biotech target?

Legend Biotech targets a wide range of liquid and solid tumors, with a significant focus on multiple myeloma.

Where does Legend Biotech generate most of its revenue?

The majority of Legend Biotech's revenue comes from the United States through license and collaboration agreements.

How successful have Legend Biotech's clinical trials been?

Their clinical trials have shown promising results, particularly in treating patients with refractory and relapsed multiple myeloma.

Who are Legend Biotech's collaborators?

Legend Biotech collaborates with leading immunologists and molecular biologists to advance their research and development.

What is the vision behind Legend Biotech's founding?

The company was founded on the vision of safely and effectively treating previously incurable cancers with innovative technology.

What is unique about Legend Biotech's technology platform?

Their platform focuses on developing finely-tuned CAR-T products, which have demonstrated significant clinical success.

How can I stay updated on Legend Biotech's latest news?

You can stay updated by following the latest news and developments on their dedicated page on StockTitan.

Legend Biotech Corporation

Nasdaq:LEGN

LEGN Rankings

LEGN Stock Data

9.91B
363.82M
1.32%
49.04%
6.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Somerset